?个人简介
工作职位：制药工程教研室副教授
办公地址：青岛科技大学科技北园609室
工作邮箱：shanshandu000@163.com
2011硕士毕业于山东大学药学院，2014年获得德国海德堡大学博士学位。2018年来校工作前在清华大学化学工程系从事博士后研究，并在药明生物从事抗体药物研发的工作。主要研究领域包括生物制药、多糖类药物开发与研究等。
?教学情况
1、本科生课程
药物分析：32课时，本科生，约60人。
?论文
[1] Du S, Krämer S, Harenberg J, et al. Chromogenic assays for measurement rivaroxaban from EDTA anticoagulated plasma samples [J]. Thromb Haemost. 2015, Jan 113(5): 1149-51.
[2] Du S, Weiss C, Harenberg J, et al. Determination of dabigatran concentrations in patient plasma, serum and urine samples: comparison of six methods [J]. Clin Chem Lab Med, 2015, Jul 53(8):1237-47.
[3] Du S, Harenberg J, Krämer S, et al. Measurement of non-vitamin K antagonist oral anticoagulants in patient plasma using Heptest-STAT coagulation method [J]. Ther Drug Monit. 2015 Jun, 37(3):375-80.
[4] Qi YK, Si Y, Du S, et al. Recent advances in the chemical synthesis and semi-synthesis of poly-ubiquitin-based proteins and probes. [J] Sci China Chem, 2019 Jan, 62: 299-312
[5] Yan YS, Du S, Yang J, et al. Discovery of enzymatically depolymerized heparins capable of treating Bleomycin-induced pulmonary injury and fibrosis in mice. [J] Carbohydr Polym, 2017 June, 174: 82-88
[6] Harenberg J, Du S, et al. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study [J]. Clin Chem Lab Med, 2016 Feb, 54(2):275-83
[7] Harenberg J, Du S, et al. Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants [J]. Semin Thromb Hemost. 2015 Mar, 41(2):228-36.
[8] Harenberg J, Du S, Weiss C, et al. Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH [J], J Thromb Haemost, 2014 May, 12: 801-804.
[9] Du S, Harenberg J, Krämer S, Marx S, et al. Determination of dabigatran and rivaroxaban in serum samples from patients on treatment. Poster session presented at: International Society on Thrombosis and Haemostasis 24th Congress, 2013 June 29 - July 4; Amsterdan.
[10] Harenberg J, Kramer S, Du S, et al. Measurement of rivaroxaban and apixaban in serum samples of patients [J]. Eur J Clin Invest. 2014 Aug, 44 (8):743–52.
[11] Harenberg J, Krämer S, Du S, et al. Determination of direct oral anticoagulants from human serum samples [J], Semin Thromb Hemost. 2014 Feb, 40 (1):129 - 34.
[12] Harenberg J, Du S, Krämer S, et al. Novel Methods for Assessing Oral Direct Factor Xa and Thrombin Inhibitors: Use of Point-of-Care Testing and Urine Samples [J], Semin Thromb Hemost 2013 Feb, 39: 66-71.
[13] Harenberg J, Krämer S, Du S, et al. Concept of a point of care test to detect new oral anticoagulants in urine samples [J], Thrombosis Journal 2013 Aug, 11: 15.
[14] Yan YS, Guan CG, Du S, et al. Effects of enzymatically depolymerized low molecular weight heparins on CCl4-induced liver fibrosis. [J] Front in pharmacol, 2017 Aug, 8:514
[15] Li Y, Luo JY, Cui HF, Zheng L, Du S, et al. Study on anti-metasis of heparin derivatives as ligand antagonist of p-selectin [J]. Biomed Pharmacother 2010 Dec, 64: 654-658.
[16]杜姗姗,崔慧斐.低分子肝素分子量测定方法[J],药物分析杂志, 2011, 31(2): 402-408.
[17]杜姗姗,桑青,崔慧斐.低分子肝素分子量测定用对照品的研制[J],药物分析杂志, 2012, 32 (11): 1976–1980.
?承担的科研项目
[1] 2016.01–2017.12，中国博士后基金，2015M581121，肝素的修饰及其对治疗特发性肺纤维化影响规律的研究，已结题，项目负责人。
[2] 201907-202206，山东省基金，ZR2019BH045，肝素及其衍生物对脓毒症治疗作用的研究，在研，项目负责人。


上一条：吴汝林
下一条：沈勇